EnilloRing 0.12 mg / 0.015 mg per 24HR 3 Week Vaginal System
RxNorm 2644707

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2644707 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: EnilloRing 0.12 mg / 0.015 mg per 24HR 3 Week Vaginal System.

The following semantic concepts and normalized strings are associated with this clinical entity:

SBD
21 DAY ethinyl estradiol 0.000625 mg/HR / etonogestrel 0.005 mg/HR Vaginal System [Enilloring]
AUI:12827437
View
PSN
EnilloRing 0.12 mg / 0.015 mg per 24HR 3 Week Vaginal System
AUI:12827442
View
SY
EnilloRing 0.12/0.015 mg per 24HR 21 Day Vaginal System
AUI:12827439
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDPrescribable

Semantic Branded Drug (SBD):
21 DAY ethinyl estradiol 0.000625 mg/HR / etonogestrel 0.005 mg/HR Vaginal System [Enilloring]
(Atom ID: 12827437)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
21 DAY ethinyl estradiol 0.000625 MG/HR / etonogestrel 0.005 MG/HR Vaginal System [Enilloring]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2644707
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12827437
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBD
Semantic Branded Drug (Ingredient + Strength + Dose Form + Brand Name)
Source Code
2644707
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN AI
{1367432} 4124
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AI
{798355} 14584
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AM
{1367432} 4124
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AM
{798355} 14584
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AVAILABLE STRENGTH
0.000625 MG/HR / 0.005 MG/HR
Available drug strengths listed in the order of ingredients from the drug
RXN BOSS FROM
{1367432} AI
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN BOSS FROM
{798355} AI
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN HUMAN DRUG
US
Drug available for use in Humans
RXN QUANTITY
21 DAY
Normal Form quantity factor
PSNPrescribable

Prescribable Name (PSN):
EnilloRing 0.12 mg / 0.015 mg per 24HR 3 Week Vaginal System
(Atom ID: 12827442)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
EnilloRing 0.12 MG / 0.015 MG per 24HR 3 Week Vaginal System
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2644707
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12827442
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
2644707
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
SYPrescribable

Synonym (SY):
EnilloRing 0.12/0.015 mg per 24HR 21 Day Vaginal System
(Atom ID: 12827439)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
EnilloRing 0.12/0.015 MG per 24HR 21 Day Vaginal System
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2644707
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12827439
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
2644707
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Estrogen and Progestin (Vaginal Ring Contraceptives)


Estrogen and progestin vaginal ring contraceptives are used to prevent pregnancy. Estrogen (ethinyl estradiol) and progestin (etonogestrel or segesterone) are two female sex hormones. Estrogen and progestin are in a class of medications called combination hormonal contraceptives (birth control medications). Combinations of estrogen and progestin work by preventing ovulation (the release of eggs from the ovaries). They also change the lining of the uterus (womb) to prevent pregnancy from developing and change the mucus at the cervix (opening of the uterus) to prevent sperm (male reproductive cells) from entering. Contraceptive vaginal rings are a very effective method of birth control, but they do not prevent the spread of human immunodeficiency virus (HIV, the virus that causes acquired immunodeficiency syndrome [AIDS]) and other sexually transmitted diseases.
[Learn More]


* Please review the disclaimer below.